<DOC>
	<DOC>NCT00546624</DOC>
	<brief_summary>This study will determine the effectiveness of MK0777 GEM versus Lorazepam in the treatment of patients with generalized anxiety disorder. This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).</brief_summary>
	<brief_title>GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD (0777-026)</brief_title>
	<detailed_description />
	<mesh_term>Anxiety Disorders</mesh_term>
	<criteria>Have been diagnosed with Generalized Anxiety Disorder Women of childbearing potential must use a doublebarrier methods of contraception and must have a negative blood pregnancy test at the beginning of the study History of drug or alcohol abuse Have previously participated in another study using MK0777</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>